Erschienen in:
01.11.2016
Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study
verfasst von:
Bark Betzel, Jens Homan, Edo O. Aarts, Ignace M. C. Janssen, Hans de Boer, Peter J. Wahab, Marcel J. M. Groenen, Frits J. Berends
Erschienen in:
Surgical Endoscopy
|
Ausgabe 7/2017
Einloggen, um Zugang zu erhalten
Abstract
Background
The duodenal-jejunal bypass liner (DJBL) is an endoscopic treatment for patients with type 2 diabetes mellitus (T2DM) and (morbid) obesity. The aim of the current study was to determine its efficacy and safety profile.
Methods
Inclusion criteria for treatment with a DJBL were: age 18–70 years, BMI 28–45 kg/m2, and T2DM with a HbA1c > 48 mmol/mol. Primary outcomes were changes in HbA1c and body weight. Secondary outcomes included changes in blood pressure, lipids, and anti-diabetic medication. Predictive factors for success of treatment with the DJBL were determined.
Results
Between 2011 and 2014, 185 out of 198 patients successfully underwent a DJBL implantation procedure, with an intended implantation time of 12 months. In these 185 patients, body weight decreased by 12.8 ± 8.0 kg (total body weight loss of 11.9 ± 6.9 %, p < 0.001), HbA1c decreased from 67 to 61 mmol/mol (p < 0.001) despite a reduction in anti-diabetic medication, and blood pressure and serum lipid levels all decreased. In total, 57 (31 %) DJBLs were explanted early after a median duration of 33 weeks. Adverse events occurred in 17 % of patients. C-peptide ≥1.0 nmol/L and body weight ≥107 kg at screening were independent predictive factors for success.
Conclusions
Treatment with the DJBL in T2DM patients with (morbid) obesity results in improvement in glucose control, a reduction in anti-diabetic medication, and significant weight loss. The largest changes are observed within the first 3–6 months. Initial C-peptide levels and body weight may help to select patients with the greatest chance of success.